Haldol Decanoas (Haloperidol Decanoate)

Haloperidol decanoate is indicated for the treatment of several psychotic disorders and is administered by a healthcare professional. It is commonly employed in long‑term management strategies where oral therapy is unsuitable.

• Maintenance therapy for chronic schizophrenia when oral adherence is challenging.
• Acute control of severe psychotic episodes requiring rapid symptom stabilization.
• Adjunctive treatment in patients with schizoaffective disorder.
• Management of acute agitation in hospitalized settings.
• Use in patients with bipolar disorder experiencing psychotic features.

Haloperidol decanoate may cause a range of adverse effects, some of which are more frequently observed than others. Patients should be monitored regularly for any new or worsening symptoms.

Common

• Extrapyramidal symptoms such as tremor, rigidity, or akathisia.
• Drowsiness or sedation, especially after injection.
• Dry mouth and increased salivation.
• Constipation or gastrointestinal discomfort.

Serious

• Neuroleptic malignant syndrome, a rare but life‑threatening reaction.
• Tardive dyskinesia, characterized by involuntary movements.
• Significant orthostatic hypotension leading to dizziness.
• Elevated prolactin levels causing hormonal disturbances.

When prescribing haloperidol decanoate, clinicians should consider several safety factors to minimize risk. Individual patient history and comorbidities are important determinants.

• Assess for a history of cardiovascular disease before initiating therapy.
• Monitor for signs of extrapyramidal side effects, especially in elderly patients.
• Evaluate liver and renal function periodically.
• Use caution in patients with a known history of seizures.
• Discuss potential pregnancy and lactation risks with women of childbearing age.
• Ensure regular follow‑up to adjust dosing based on clinical response.

Haloperidol decanoate can interact with other medications, altering its efficacy or increasing the likelihood of adverse events. Review all concurrent drugs before starting treatment.

Avoid

• Concurrent use with other dopamine antagonists, which may amplify extrapyramidal effects.
• Strong CYP3A4 inhibitors such as ketoconazole, which can raise plasma concentrations.
• Medications that prolong the QT interval, increasing cardiac risk.

Use with caution

• CNS depressants like benzodiazepines, which may enhance sedation.
• Anticholinergic agents that can mask early signs of movement disorders.
• Drugs affecting electrolyte balance, such as diuretics, which may predispose to arrhythmias.